{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:36:02Z","timestamp":1784550962525,"version":"3.55.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>For some patients receiving warfarin, adding aspirin (acetylsalicylic acid) increases bleeding risk with unclear treatment benefit. Reducing excess aspirin use could be associated with improved clinical outcomes.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess changes in aspirin use, bleeding, and thrombosis event rates among patients treated with warfarin.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This pre-post observational quality improvement study was conducted from January 1, 2010, to December 31, 2019, at a 6-center quality improvement collaborative in Michigan among 6738 adults taking warfarin for atrial fibrillation and\/or venous thromboembolism without an apparent indication for concomitant aspirin. Statistical analysis was conducted from November 26, 2020, to June 14, 2021.<\/jats:p><\/jats:sec>Intervention<\/jats:title>Primary care professionals for patients taking aspirin were asked whether an ongoing combination aspirin and warfarin treatment was indicated. If not, then aspirin was discontinued with the approval of the managing clinician.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Outcomes were assessed before and after intervention for the primary analysis and before and after 24 months before the intervention (when rates of aspirin use first began to decrease) for the secondary analysis. Outcomes included the rate of aspirin use, bleeding, and thrombotic outcomes. An interrupted time series analysis assessed cumulative monthly event rates over time.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 6738 patients treated with warfarin (3160 men [46.9%]; mean [SD] age, 62.8 [16.2] years) were followed up for a median of 6.7 months (IQR, 3.2-19.3 months). Aspirin use decreased slightly from a baseline mean use of 29.4% (95% CI, 28.9%-29.9%) to 27.1% (95% CI, 26.1%-28.0%) during the 24 months before the intervention (P<\/jats:italic>\u2009&lt;\u2009.001 for slope before and after 24 months before the intervention) with an accelerated decrease after the intervention (mean aspirin use, 15.7%; 95% CI, 14.8%-16.8%; P<\/jats:italic>\u2009=\u2009.001 for slope before and after intervention). In the primary analysis, the intervention was associated with a significant decrease in major bleeding events per month (preintervention, 0.31%; 95% CI, 0.27%-0.34%; postintervention, 0.21%; 95% CI, 0.14%-0.28%; P<\/jats:italic>\u2009=\u2009.03 for difference in slope before and after intervention). No change was observed in mean percentage of patients having a thrombotic event from before to after the intervention (0.21% vs 0.24%; P<\/jats:italic>\u2009=\u2009.34 for difference in slope). In the secondary analysis, reducing aspirin use (starting 24 months before the intervention) was associated with decreases in mean percentage of patients having any bleeding event (2.3% vs 1.5%; P<\/jats:italic>\u2009=\u2009.02 for change in slope before and after 24 months before the intervention), mean percentage of patients having a major bleeding event (0.31% vs 0.25%; P<\/jats:italic>\u2009=\u2009.001 for change in slope before and after 24 months before the intervention), and mean percentage of patients with an emergency department visit for bleeding (0.99% vs 0.67%; P<\/jats:italic>\u2009=\u2009.04 for change in slope before and after 24 months before the intervention), with no change in mean percentage of patients with a thrombotic event (0.20% vs 0.23%; P<\/jats:italic>\u2009=\u2009.36 for change in slope before and after 24 months before the intervention).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This quality improvement intervention was associated with an acceleration of a preexisting decrease in aspirin use among patients taking warfarin for atrial fibrillation and\/or venous thromboembolism without a clear indication for aspirin therapy. Reductions in aspirin use were associated with reduced bleeding. This study suggests that an anticoagulation clinic\u2013based aspirin deimplementation intervention can improve guideline-concordant aspirin use.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.31973","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T15:32:15Z","timestamp":1663601535000},"page":"e2231973","source":"Crossref","is-referenced-by-count":26,"title":["Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation"],"prefix":"10.1001","volume":"5","author":[{"given":"Jordan K.","family":"Schaefer","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Errickson","sequence":"additional","affiliation":[{"name":"Consulting for Statistics, Computing, & Analytics Research, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokui","family":"Gu","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Alexandris-Souphis","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona A.","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Heart and Vascular Services, Beaumont Hospital, Royal Oak, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Haymart","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kaatz","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, Henry Ford Hospital, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kline-Rogers","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay H.","family":"Kozlowski","sequence":"additional","affiliation":[{"name":"Huron Valley Sinai Hospital, Commerce Township, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Krol","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman L.","family":"Sood","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Froehlich","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey D.","family":"Barnes","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"issue":"12","key":"zoi220916r1","doi-asserted-by":"publisher","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement.","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Ann Intern Med"},{"issue":"2","key":"zoi220916r2","doi-asserted-by":"publisher","first-page":"e637S","DOI":"10.1378\/chest.11-2306","article-title":"Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.","volume":"141","author":"Vandvik","year":"2012","journal-title":"Chest"},{"issue":"25","key":"zoi220916r3","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1161\/CIR.0b013e3182776f83","article-title":"2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.","volume":"126","author":"Fihn","year":"2012","journal-title":"Circulation"},{"issue":"12","key":"zoi220916r4","doi-asserted-by":"publisher","first-page":"e686","DOI":"10.1161\/CIR.0000000000000470","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"zoi220916r5","doi-asserted-by":"publisher","first-page":"e669S","DOI":"10.1378\/chest.11-2307","article-title":"Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.","volume":"141","author":"Alonso-Coello","year":"2012","journal-title":"Chest"},{"issue":"7","key":"zoi220916r6","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association.","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"issue":"2","key":"zoi220916r7","doi-asserted-by":"publisher","first-page":"e601S","DOI":"10.1378\/chest.11-2302","article-title":"Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.","volume":"141","author":"Lansberg","year":"2012","journal-title":"Chest"},{"issue":"4","key":"zoi220916r8","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines.","volume":"127","author":"O\u2019Gara","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"zoi220916r9","doi-asserted-by":"publisher","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"issue":"23","key":"zoi220916r10","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1161\/CIR.0000000000000029","article-title":"2014 AHA\/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"129","author":"Nishimura","year":"2014","journal-title":"Circulation"},{"issue":"2","key":"zoi220916r11","doi-asserted-by":"publisher","first-page":"e576S","DOI":"10.1378\/chest.11-2305","article-title":"Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.","volume":"141","author":"Whitlock","year":"2012","journal-title":"Chest"},{"issue":"25","key":"zoi220916r12","doi-asserted-by":"publisher","first-page":"e1159","DOI":"10.1161\/CIR.0000000000000503","article-title":"2017 AHA\/ACC focused update of the 2014 AHA\/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"135","author":"Nishimura","year":"2017","journal-title":"Circulation"},{"issue":"4","key":"zoi220916r13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/jamainternmed.2018.7816","article-title":"Association of adding aspirin to warfarin therapy without an apparent indication with bleeding and other adverse events.","volume":"179","author":"Schaefer","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"7","key":"zoi220916r14","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1161\/CIRCULATIONAHA.113.002927","article-title":"Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.","volume":"128","author":"Steinberg","year":"2013","journal-title":"Circulation"},{"issue":"4","key":"zoi220916r15","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1378\/chest.07-2627","article-title":"Outcomes associated with combined antiplatelet and anticoagulant therapy.","volume":"133","author":"Johnson","year":"2008","journal-title":"Chest"},{"issue":"1","key":"zoi220916r16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11239-016-1425-5","article-title":"Combined aspirin and anticoagulant therapy in patients with atrial fibrillation.","volume":"43","author":"So","year":"2017","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"zoi220916r17","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1378\/chest.06-2374","article-title":"Warfarin and antiplatelet combination use among commercially insured patients enrolled in an anticoagulation management service.","volume":"131","author":"Johnson","year":"2007","journal-title":"Chest"},{"issue":"6","key":"zoi220916r18","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.thromres.2011.02.010","article-title":"Combination warfarin-ASA therapy: which patients should receive it, which patients should not, and why?","volume":"127","author":"Douketis","year":"2011","journal-title":"Thromb Res"},{"issue":"2","key":"zoi220916r19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s11239-009-0413-4","article-title":"Combined warfarin-aspirin therapy: what is the evidence for benefit and harm and which patients should (and should not) receive it?","volume":"29","author":"Donadini","year":"2010","journal-title":"J Thromb Thrombolysis"},{"issue":"11","key":"zoi220916r20","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1161\/CIR.0000000000000678","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"zoi220916r21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11239-015-1184-8","article-title":"Engaging with quality improvement in anticoagulation management.","volume":"39","author":"Barnes","year":"2015","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"zoi220916r22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","article-title":"Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal\/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs\/alcohol concomitantly) score.","volume":"57","author":"Lip","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"zoi220916r23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor\u2013based approach: the Euro Heart Survey on Atrial Fibrillation.","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"11","key":"zoi220916r24","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH.","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"2","key":"zoi220916r25","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1161\/CIRCOUTCOMES.115.002366","article-title":"Reimagining anticoagulation clinics in the era of direct oral anticoagulants.","volume":"9","author":"Barnes","year":"2016","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"zoi220916r27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s11239-020-02207-3","article-title":"Evaluation and optimization of prescribed concomitant antiplatelet and anticoagulation therapy centrally managed by an anticoagulation management service.","volume":"51","author":"Zekery-Saad","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"zoi220916r28","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-021-02551-y","article-title":"Antithrombosis stewardship efforts to de-escalate inappropriate combined therapy in outpatient clinics.","author":"Meador","year":"2022","journal-title":"J Thromb Thrombolysis"},{"issue":"10186","key":"zoi220916r29","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1016\/S0140-6736(19)30541-0","article-title":"The rise and fall of aspirin in the primary prevention of cardiovascular disease.","volume":"393","author":"Raber","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"zoi220916r30","doi-asserted-by":"publisher","first-page":"596","DOI":"10.7326\/M19-0953","article-title":"Prevalence of aspirin use for primary prevention of cardiovascular disease in the United States: results from the 2017 National Health Interview Survey.","volume":"171","author":"O\u2019Brien","year":"2019","journal-title":"Ann Intern Med"},{"key":"zoi220916r31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.pmedr.2016.12.023","article-title":"Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012-2015.","volume":"5","author":"Stuntz","year":"2016","journal-title":"Prev Med Rep"},{"issue":"5","key":"zoi220916r32","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.amepre.2014.11.005","article-title":"Aspirin use among adults in the U.S.: results of a national survey.","volume":"48","author":"Williams","year":"2015","journal-title":"Am J Prev Med"},{"issue":"16","key":"zoi220916r33","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1001\/jama.2022.4983","article-title":"Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement.","volume":"327","author":"Davidson","year":"2022","journal-title":"JAMA"},{"key":"zoi220916r26","unstructured":"Michigan Anticoagulation Quality Improvement Initiative. Anticoagulation toolkit. Accessed August 8, 2022. http:\/\/www.anticoagulationtoolkit.org\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2796492\/schaefer_2022_oi_220916_1663080480.24258.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T15:32:19Z","timestamp":1663601539000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2796492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.31973","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,19]]}}}